The pharmaceutical contract manufacturing market in China is anticipated to be worth USD 13 Billion by 2030, growing at an annualized rate of ~8.9%, claims Roots Analysis

Reduced manufacturing costs, availability of cheap and skilled labor, coupled to a supportive regulatory landscape has compelled various drug developers across the globe to outsource their pharmaceutical manufacturing operations to China 

Roots Analysis has announced the addition of “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030” report to its list of offerings. 

A growing economy, large population base, and innovation-friendly environment are other key parameters that are anticipated to drive the growth of the pharmaceutical contract manufacturing market in China. Further, in order to meet the growing demand for their services, CMOs having manufacturing facilities in China are actively expanding their existing capacities and capabilities in the region. 

To order this 200+ page report, which features 85+ figures and 100+ tables, please visit this link

Key Market Insights

Over 100 CMOs claim to have established their pharmaceutical manufacturing facilities in China 
Presently, the contract services market in China dominated by the presence of large and very large CMOs, which represent ~70% of stakeholders in this industry. Further, it is worth highlighting that 89% CMOs having facilities in China provide services for the production of pharmaceutical APIs. 

~73% of the pharmaceutical manufacturing facilities are based in Eastern China 
Key manufacturing hubs within Eastern China (in terms of number of manufacturing facilities) include (in decreasing number of manufacturing facilities) Jiangsu, Zhejiang, Shanghai and Shandong. Apart from this, CMOs have also established their pharmaceutical manufacturing facilities in some emerging regions of Southern China and Northern China.

Around 90% of the total, installed pharmaceutical API contract manufacturing capacity belongs to large / very large firms 
The current, installed pharmaceutical API contract manufacturing capacity in China is estimated to be around 46 million L. Further, it is worth noting that 73% of the overall production capacity is contributed by facilities based in Eastern China. As mentioned earlier, this can be attributed to the larger number of facilities established in the aforementioned region.

Several big pharma players have invested in pharmaceutical manufacturing initiatives in China
Close to half of the aforementioned initiatives were observed to be related to the establishment / expansion of pharmaceutical manufacturing facilities in China. Further, it is worth highlighting that, around 50% of the big pharma initiatives were reported to be initiated post 2010. 

By 2030, API segment is anticipated to capture 66% share (in terms of service revenue) of the pharmaceutical contract manufacturing market in China 
In 2020, the outsourced component of the pharmaceutical manufacturing services market in China is estimated to be worth USD 5.5 billion. Further, majority share of contract service revenues is estimated to be generated from commercial scale operations, and this trend is unlikely to change in the foreseen future as well.

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

• Who are the leading China-based pharmaceutical CMOs engaged in the production of APIs, intermediates and FDFs?
• What are the key manufacturing hubs within China (in terms of number of manufacturing facilities)?
• What is the current installed capacity for manufacturing of pharmaceuticals, in China?
• What are the major market trends and driving factors that are likely to impact the growth of the pharmaceutical manufacturing market in China?
• What is the likely short-term and long-term impact of the COVID-19 pandemic on the pharmaceutical contract manufacturing industry in China? 
• What kind of initiatives are being undertaken by big pharmaceutical players for pharmaceutical manufacturing in China? 
• How is the current and future market opportunity likely to be distributed across key market segments?

The USD 13 billion (by 2030) financial opportunity within the pharmaceuticals contract manufacturing market in China has been analyzed across the following segments:

• Key Geographical Regions
  • Eastern China
  • Southern China
  • Northern China 
• Type of Product 
  • Active Pharmaceutical Ingredients (APIs)
  • Drug Products
• Type of Drug Product
  • Solid
  • Liquid / Semi-Solid
  • Injectable
  • Others
• Scale of Operation
  • Clinical
  • Commercial
• Company Size
  • Small
  • Mid-Sized
  • Large / Very Large

The research covers brief profiles of several key players (including those listed below); each profile features an overview of the company, its financial information (if available), pharmaceutical manufacturing services portfolio in China, recent developments, and an informed future outlook.

• 2Y-Chem 
• Aurisco Pharmaceutical 
• ChemPartner 
• Dorrapharma 
• Hubei Biocause Pharmaceutical 
• Infoark 
• Ningbo Menovo Pharmaceutical 
• Shandong Xinhua Pharmaceutical 
• Shanghai Acebright Pharmaceuticals 
• STA Pharmaceutical 
• Zhejiang Huahai Pharmaceutical 

For additional details, please visit 
https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html

or email sales@rootsanalysis.com

You may also be interested in the following titles: 

1. China Biopharmaceutical Contract Manufacturing Market, 2020 – 2030
2. HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030
3. Novel coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development

Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com